| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.049 | 0.5 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.037 | 0.5 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |